| Pharmaceutical Economics and Policy | Lifetime | 19 | GB 3 | 99.28 |
| Global Health Care Issues | Lifetime | 52 | GB 12 | 99.27 |
| Healthcare Systems and Reforms | Lifetime | 28 | GB 5 | 99.17 |
| Healthcare Policy and Management | Lifetime | 119 | GB 14 | 99.05 |
| Health Systems, Economic Evaluations, Quality of Life | Lifetime | 291 | GB 55 | 99.13 |
| Biosimilars and Bioanalytical Methods | Lifetime | 63 | GB 6 | 98.39 |
| Economic and Financial Impacts of Cancer | Lifetime | 154 | GB 9 | 97.95 |
| Global Maternal and Child Health | Lifetime | 848 | GB 119 | 97.24 |
| Global Public Health Policies and Epidemiology | Lifetime | 322 | GB 52 | 96.44 |
| Antibiotic Use and Resistance | Lifetime | 451 | GB 48 | 97.25 |
| Health Services Management and Policy | Lifetime | 25 | GB 7 | 95.60 |
| Primary Care and Health Outcomes | Lifetime | 634 | GB 108 | 96.79 |
| COVID-19 Pandemic Impacts | Lifetime | 281 | GB 24 | 93.95 |
| Employment and Welfare Studies | Lifetime | 648 | GB 131 | 95.93 |
| Healthcare cost, quality, practices | Lifetime | 371 | GB 54 | 95.43 |
| Pharmaceutical industry and healthcare | Lifetime | 161 | GB 12 | 94.24 |
| Healthcare Systems and Public Health | Lifetime | 937 | GB 10 | 89.34 |
| Genetically Modified Organisms Research | Lifetime | 467 | GB 51 | 90.27 |
| Risk Perception and Management | Lifetime | 490 | GB 76 | 88.03 |
| Healthcare Systems and Challenges | Lifetime | 213 | GB 93 | 84.67 |
| Climate Change Communication and Perception | Lifetime | 854 | GB 122 | 84.83 |
| Health and Conflict Studies | Lifetime | 642 | GB 95 | 81.26 |
| Healthcare Systems and Reforms | 2021-2025 | 12 | GB 2 | 98.78 |
| Global Health Care Issues | 2021-2025 | 24 | GB 4 | 98.07 |
| Health Systems, Economic Evaluations, Quality of Life | 2021-2025 | 136 | GB 24 | 98.20 |
| Global Maternal and Child Health | 2021-2025 | 95 | GB 11 | 98.32 |
| Global Public Health Policies and Epidemiology | 2021-2025 | 104 | GB 17 | 93.63 |
| Pharmaceutical Economics and Policy | 2021-2025 | 65 | GB 7 | 95.13 |
| Healthcare Policy and Management | 2021-2025 | 131 | GB 5 | 95.03 |
| Economic and Financial Impacts of Cancer | 2021-2025 | 182 | GB 8 | 94.33 |
| Healthcare cost, quality, practices | 2021-2025 | 98 | GB 13 | 92.80 |
| Vaccine Coverage and Hesitancy | 2021-2025 | 420 | GB 48 | 94.66 |
| Health disparities and outcomes | 2021-2025 | 671 | GB 99 | 92.15 |
| Biosimilars and Bioanalytical Methods | 2021-2025 | 185 | GB 12 | 90.66 |
| COVID-19 Pandemic Impacts | 2021-2025 | 327 | GB 20 | 91.02 |
| Antibiotic Use and Resistance | 2021-2025 | 472 | GB 52 | 91.22 |
| Primary Care and Health Outcomes | 2021-2025 | 319 | GB 32 | 89.59 |
| Health and Conflict Studies | 2021-2025 | 59 | GB 8 | 86.77 |
| Viral Infections and Outbreaks Research | 2021-2025 | 542 | GB 64 | 84.59 |
| Food Security and Health in Diverse Populations | 2021-2025 | 815 | GB 45 | 84.36 |
| Healthcare Systems and Public Health | 2021-2025 | 467 | GB 3 | 81.80 |
| Telemedicine and Telehealth Implementation | 2021-2025 | 620 | GB 57 | 82.37 |
| Clinical practice guidelines implementation | 2021-2025 | 713 | GB 99 | 70.35 |
| Pharmaceutical industry and healthcare | 2021-2025 | 162 | GB 17 | 69.12 |
| Healthcare Systems and Challenges | 2021-2025 | 110 | GB 37 | 65.12 |
